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Power calculations were performed in the planning phase of the study. These showed that a sample of 128 children in each treatment group was required to detect an absolute difference of 15% in the incidence of renal scarring between the two groups, with a power of 0.80 and a statistical significance of 0.05. The initial sample of eligible children included 421 patients. Of these, 23 refused to participate and 76 were not enrolled (investigator not available, use of prior antibiotics, language barrier, primary care provider refuses or out-of-state residence). Of the remaining 322 enrolled patients, 13 had a negative urine culture, and 3 were deemed to be too sick to be involved. Thus, the final sample included in the effectiveness study comprised 306 patients, 153 in each group. The mean age in the oral group was 8.8 (+/-5.9) months and 88.9% were female. The mean age in the i.v. group was 8.3 (+/-5.6) months and 89.6% were female. No statistically significant differences between the two groups were found.
Study design
This was a randomised clinical trial that was carried out in four centres. The unit of randomisation was each clinical centre. The children were allocated to the study treatments within strata based on age (1 to 12 or 13 to 24 months) and duration of fever (less than 48 or at least 48 hours). The overall follow-up was 6 months. The loss to follow-up was 13 patients (8.5%) in the oral group and 6 patients (3.9%) in the control group.
The outcomes for inpatients were assessed on daily rounds and by contacting the parents at 48 hours after discharge and 10 days after study entry. The parents of children treated orally were contacted monthly by telephone and at 48 hours and 10 days after study entry. A follow-up outpatient visit was performed at about 14 days for all participants. All episodes of reinfection were recorded and the children were treated according to the protocol to which they were initially assigned. The assessment was also performed by renal scans. These were interpreted independently by two physician investigators who were unaware of the child's treatment assignment (single blinding).
Analysis of effectiveness
The basis of the analysis of the clinical study was intention to treat. The health outcomes used in the analysis were:
the results of the 99mTc-dimercaptosuccinic acid (DMSA) renal scan and the VCUG performed at the beginning of the study and at the follow-up assessment, the occurrence of defervescence, the incidence of reinfection, the degree of scarring, bacteraemia, and compliance.
Logistic regression analysis was used to evaluate the impact of specific patient characteristics on the estimated outcome measures. The patients in the study groups were comparable at baseline in terms of their demographic and clinical characteristics.
Effectiveness results
There was no significant difference in any of the outcome measures used in the effectiveness analysis.
The incidence of renal scarring over the whole study period was 9.8% in the oral group and 7.2% in the i.v. group, (p=0.21). The authors reported there was "no significant difference between...the incidence of new renal scarring...or extent (severity) of scarring" between the treatment groups.
The results of the DMSA and VCUG were comparable between the two groups. The incidence of reinfection was also comparable.
